A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola

Trial Profile

A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine
  • Indications Ebola virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms EBOVAC-Salone
  • Sponsors Janssen Vaccines and Prevention
  • Most Recent Events

    • 09 Oct 2017 Planned End Date changed from 12 May 2019 to 13 May 2019.
    • 09 Oct 2017 Planned primary completion date changed from 30 Sep 2018 to 3 May 2019.
    • 21 Mar 2017 Planned number of patients changed from 728 to 1019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top